Khaled Ezzedine, Ahmed M Soliman, Mary Kathleen Ladd, Stavonnie Patterson, Rohini Sen, Sarah Ofori, Karin S Coyne, Robin Pokrzywinski
{"title":"诊断为白癜风患者的生活经验和初步概念疾病模型:来自患者,患者倡导者和临床医生的见解。","authors":"Khaled Ezzedine, Ahmed M Soliman, Mary Kathleen Ladd, Stavonnie Patterson, Rohini Sen, Sarah Ofori, Karin S Coyne, Robin Pokrzywinski","doi":"10.1007/s13555-025-01510-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Patients with vitiligo experience high disease and psychosocial burden, and dissatisfaction with current treatment options, highlighting a need to understand the disease from a patient perspective. This study gathered insights from key opinion leaders (KOLs) and patient advocates on a conceptual disease model of vitiligo and gained patient perspectives through qualitative interviews on the disease burden and concepts important to patients with nonsegmental vitiligo (NSV), and what degree and anatomical location of repigmentation may constitute a meaningful change with treatment.</p><p><strong>Methods: </strong>This cross-sectional, observational study involved virtual, semi-structured, qualitative interviews with expert KOLs treating patients with vitiligo, patient advocates, and patients diagnosed with NSV.</p><p><strong>Results: </strong>Patient advocates (n = 5) and KOLs (n = 6) felt that the conceptual disease model comprehensively captured the signs, symptoms, and impact of vitiligo, and had minor changes including reordering symptoms. Of 22 patients interviewed, most experienced depigmentation on their arms, trunk, hands, feet; and 86.4% had vitiligo on their face. The most frequently reported sign or symptom was increased sensitivity to the sun (82%). Patients reported that vitiligo broadly impacts many facets of life, most commonly emotional well-being (82%). Patients reported that perceived treatment success is driven by the extent of vitiligo repigmentation, especially on the face and hands, and would consider 20-25% repigmentation a meaningful improvement.</p><p><strong>Conclusion: </strong>This study provides insight into the lived experience of patients with NSV, and alignment from patient advocates and KOLs on the conceptual disease model of vitiligo. The findings increase our understanding and inform vitiligo clinical studies.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2967-2981"},"PeriodicalIF":4.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454719/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Lived Experience of Patients Diagnosed with Vitiligo and a Preliminary Conceptual Disease Model: Insights from Patients, Patient Advocates, and Clinicians.\",\"authors\":\"Khaled Ezzedine, Ahmed M Soliman, Mary Kathleen Ladd, Stavonnie Patterson, Rohini Sen, Sarah Ofori, Karin S Coyne, Robin Pokrzywinski\",\"doi\":\"10.1007/s13555-025-01510-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Patients with vitiligo experience high disease and psychosocial burden, and dissatisfaction with current treatment options, highlighting a need to understand the disease from a patient perspective. This study gathered insights from key opinion leaders (KOLs) and patient advocates on a conceptual disease model of vitiligo and gained patient perspectives through qualitative interviews on the disease burden and concepts important to patients with nonsegmental vitiligo (NSV), and what degree and anatomical location of repigmentation may constitute a meaningful change with treatment.</p><p><strong>Methods: </strong>This cross-sectional, observational study involved virtual, semi-structured, qualitative interviews with expert KOLs treating patients with vitiligo, patient advocates, and patients diagnosed with NSV.</p><p><strong>Results: </strong>Patient advocates (n = 5) and KOLs (n = 6) felt that the conceptual disease model comprehensively captured the signs, symptoms, and impact of vitiligo, and had minor changes including reordering symptoms. Of 22 patients interviewed, most experienced depigmentation on their arms, trunk, hands, feet; and 86.4% had vitiligo on their face. The most frequently reported sign or symptom was increased sensitivity to the sun (82%). Patients reported that vitiligo broadly impacts many facets of life, most commonly emotional well-being (82%). Patients reported that perceived treatment success is driven by the extent of vitiligo repigmentation, especially on the face and hands, and would consider 20-25% repigmentation a meaningful improvement.</p><p><strong>Conclusion: </strong>This study provides insight into the lived experience of patients with NSV, and alignment from patient advocates and KOLs on the conceptual disease model of vitiligo. The findings increase our understanding and inform vitiligo clinical studies.</p>\",\"PeriodicalId\":11186,\"journal\":{\"name\":\"Dermatology and Therapy\",\"volume\":\" \",\"pages\":\"2967-2981\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454719/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13555-025-01510-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01510-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
The Lived Experience of Patients Diagnosed with Vitiligo and a Preliminary Conceptual Disease Model: Insights from Patients, Patient Advocates, and Clinicians.
Introduction: Patients with vitiligo experience high disease and psychosocial burden, and dissatisfaction with current treatment options, highlighting a need to understand the disease from a patient perspective. This study gathered insights from key opinion leaders (KOLs) and patient advocates on a conceptual disease model of vitiligo and gained patient perspectives through qualitative interviews on the disease burden and concepts important to patients with nonsegmental vitiligo (NSV), and what degree and anatomical location of repigmentation may constitute a meaningful change with treatment.
Methods: This cross-sectional, observational study involved virtual, semi-structured, qualitative interviews with expert KOLs treating patients with vitiligo, patient advocates, and patients diagnosed with NSV.
Results: Patient advocates (n = 5) and KOLs (n = 6) felt that the conceptual disease model comprehensively captured the signs, symptoms, and impact of vitiligo, and had minor changes including reordering symptoms. Of 22 patients interviewed, most experienced depigmentation on their arms, trunk, hands, feet; and 86.4% had vitiligo on their face. The most frequently reported sign or symptom was increased sensitivity to the sun (82%). Patients reported that vitiligo broadly impacts many facets of life, most commonly emotional well-being (82%). Patients reported that perceived treatment success is driven by the extent of vitiligo repigmentation, especially on the face and hands, and would consider 20-25% repigmentation a meaningful improvement.
Conclusion: This study provides insight into the lived experience of patients with NSV, and alignment from patient advocates and KOLs on the conceptual disease model of vitiligo. The findings increase our understanding and inform vitiligo clinical studies.
期刊介绍:
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.